Pembrolizumab

Common brands: Keytruda, Carboplatin, Kyxata, Lenvima, Abraxane

Top reporter: Merck Sharp & Dohme Llc

Programmed Death Receptor-1 Blocking Antibody [EPC]Platinum-based Drug [EPC]Kinase Inhibitor [EPC]Microtubule Inhibitor [EPC]Folate Analog Metabolic Inhibitor [EPC]
100,428
Total Reports
73,843
Serious Reports
18,175
Death Reports
30
Reported Reactions
Death Report Ratio: High (18.10%)

Patient Demographics

Male
46,785
Female
47,325

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Pembrolizumab.

# Reaction Reports % of Total
1 MALIGNANT NEOPLASM PROGRESSION 11,562
12.3%
2 DEATH 5,718
6.1%
3 DIARRHOEA 5,487
5.8%
4 FATIGUE 4,928
5.2%
5 OFF LABEL USE 4,623
4.9%
6 PYREXIA 3,745
4.0%
7 RASH 3,554
3.8%
8 PRODUCT USE IN UNAPPROVED INDICATION 3,468
3.7%
9 NAUSEA 3,449
3.7%
10 DECREASED APPETITE 3,216
3.4%
11 HYPERTENSION 3,102
3.3%
12 HYPOTHYROIDISM 2,799
3.0%
13 ASTHENIA 2,688
2.8%
14 DRUG INEFFECTIVE 2,498
2.6%
15 PRODUCT USE ISSUE 2,494
2.6%
16 INTERSTITIAL LUNG DISEASE 2,434
2.6%
17 MALAISE 2,328
2.5%
18 ACUTE KIDNEY INJURY 2,314
2.5%
19 ANAEMIA 2,276
2.4%
20 DYSPNOEA 2,269
2.4%
21 NEUTROPENIA 2,251
2.4%
22 PNEUMONIA 2,135
2.3%
23 PNEUMONITIS 2,134
2.3%
24 VOMITING 2,130
2.3%
25 NEUROPATHY PERIPHERAL 1,898
2.0%
26 COLITIS 1,858
2.0%
27 ARTHRALGIA 1,855
2.0%
28 WEIGHT DECREASED 1,774
1.9%
29 THROMBOCYTOPENIA 1,703
1.8%
30 RENAL IMPAIRMENT 1,688
1.8%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.